Abstract
Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma B-lymphocytes and even as of today, it is an incurable disease. MM accounts for approximately 10% of all hematologic cancers. Its molecular pathogenesis is poorly understood, but the bone marrow microenvironment of tumor cells and genetic factors have apparent roles in the process. Accurate diagnosis is important to properly identify and stratify the disease, however, MM identification steps are time-consuming and expensive. Thus, development of early molecular diagnostic methods is of high importance in order to start proper therapies as early in the disease progression as possible, given the nature of the poor survival rates/remission periods. Molecular diagnostics via analytical omics represents one of the promising toolsets to speed up the diagnostic process. In this paper, we critically review the utilization of state of the art, high sensitivity analytical omics approaches (genomics, proteomics, metabolomics, lipidomics and glycomics) in MM diagnostics at the molecular level.
Keywords: Multiple myeloma, molecular diagnostics, genomics, proteomics, metabolomics, lipidomics, glycomics.
Current Molecular Medicine
Title:Utilization of Analytical Omics Tools in the Molecular Diagnostics of Multiple Myeloma
Volume: 18 Issue: 4
Author(s): Z. Kovacs and A. Guttman*
Affiliation:
- Horvath Csaba Laboratory of Bioseparation Sciences, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen 4032,Hungary
Keywords: Multiple myeloma, molecular diagnostics, genomics, proteomics, metabolomics, lipidomics, glycomics.
Abstract: Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma B-lymphocytes and even as of today, it is an incurable disease. MM accounts for approximately 10% of all hematologic cancers. Its molecular pathogenesis is poorly understood, but the bone marrow microenvironment of tumor cells and genetic factors have apparent roles in the process. Accurate diagnosis is important to properly identify and stratify the disease, however, MM identification steps are time-consuming and expensive. Thus, development of early molecular diagnostic methods is of high importance in order to start proper therapies as early in the disease progression as possible, given the nature of the poor survival rates/remission periods. Molecular diagnostics via analytical omics represents one of the promising toolsets to speed up the diagnostic process. In this paper, we critically review the utilization of state of the art, high sensitivity analytical omics approaches (genomics, proteomics, metabolomics, lipidomics and glycomics) in MM diagnostics at the molecular level.
Export Options
About this article
Cite this article as:
Kovacs Z. and Guttman A.*, Utilization of Analytical Omics Tools in the Molecular Diagnostics of Multiple Myeloma, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666181008112738
DOI https://dx.doi.org/10.2174/1566524018666181008112738 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Preface (Hot Topic: Bioactive Peptides from Food Proteins Executive Editor: Antonio Pellegrini )
Current Pharmaceutical Design 10 Years of SELDI: What Have we Learnt?
Current Proteomics Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology A Review of Cationic Arylfurans and Their Isosteres: Synthesis and Biological Importance
Current Organic Chemistry A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Kidney Diseases and Chemokines
Current Drug Targets MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Current Drug Targets Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Emerging Facts on Chronic Consumption of Aspartame as Food Additive
Current Nutrition & Food Science